Previous issue | Volume 84 | ESPE2015 | Next issue

54th Annual ESPE

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

Card image cap
Barcelona, Spain; 1-3 October 2015 Further information

Free Communications

Endocrine Oncology/Turner

hrp0084fc5.1 | Endocrine Oncology/Turner | ESPE2015

Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in PTEN-deficient Lipoma Cells by Suppressing p70S6 Kinase Activity

Leipert Jenny , Kassner Franziska , Schuster Susanne , Handel Norman , Korner Antje , Kiess Wieland , Garten Antje

Background: Patients with PTEN (phosphatase and tensin homolog) hamartoma tumor syndrome and germ line mutations in PTEN frequently develop lipomatosis, for which there is no standard treatment. Rapamycin was shown to reduce the growth of lipoma cells with heterozygous PTEN deficiency in vitro, but concomitantly induced an up regulation of AKT phosphorylation.Objective and hypotheses: Since it was shown that resveratrol stabilizes PTEN,...

hrp0084fc5.2 | Endocrine Oncology/Turner | ESPE2015

MEN1 Syndrome Because of Combined Germline and Somatic Mosaicism, with Important Consequences for Relatives

Kempers Marlies , Stikkelbroeck Nike , Mensenkamp Arjen , Pfundt Rolph , van der Luijt Rob , Timmers Henri , Claahsen Hedi , Hoogerbrugge Nicoline , Hermus Ad

Background: Multiple endocrine neoplasia type I (MEN1) is characterized by the combined occurrence of tumours in several endocrine tissues such as parathyroid tumours, pituitary tumours (usually prolactinomas) and pancreatic neuroendocrine tumours. MEN1 is an autosomal dominant disorder caused by germline mutations in the tumour suppressor gene MEN1. First-degree relatives of a germline MEN1 mutation carrier have a 50% risk of the mutation. Intensive surveillance of g...

hrp0084fc5.3 | Endocrine Oncology/Turner | ESPE2015

Screening in Children with Succinate Dehydrogenase B (SDHB) Mutations: a Single Centre’s Family Clinic Experience

Shapiro Lucy , Srirangalingam Umasuthan , McAndrew Lorraine , Martin Lee , Tufton Nicola , Kumar Ajith , Drake William , Akker Scott , Storr Helen

Background: Germline mutations in SDHB gene are associated with the familial paraganglioma (PGL) syndrome that carries the highest malignant potential. Although penetrance is lower than initially described, lack of effective treatments for metastatic PGLs makes screening essential for early tumour detection, surgical removal and improved outcome. However, no consensus exists in relation to timing and mode of screening.Objective: To assess publis...

hrp0084fc5.4 | Endocrine Oncology/Turner | ESPE2015

X Chromosome Gene Dosage and the Risk of Developing Congenital and Acquired Traits in Turner Syndrome: a Cross-Sectional Database Analysis of the French National Rare Disease Network

Zenaty Delphine , Fiot Elodie , Boizeau Priscilla , Haignere Jeremie , Santos Sophie Dos , Carel Jean Claude , Leger Juliane , French Turner Syndrome Study Group

Background: The broad spectrum of associated diseases underlying the diverse phenotypes of patients with Turner syndrome (TS) has been extensively described. However, the underlying pathophysiological mechanisms remain unknown. Few studies have analyzed congenital and acquired diseases as a function of karyotype, and conflicting results have been obtained, calling into question the role of haploinsufficiency for genes located on the X chromosome.Objectiv...

hrp0084fc5.5 | Endocrine Oncology/Turner | ESPE2015

Hereditary Turner Syndrome 46,X,rec(X)inv(p21q28) in Six Women and Four Generations: Estimation of Skeletal Effects of GH Treatment

Stoklasova Judith , Kaprova Jana , Trkova Marie , Nedomova Vera , Zemkova Daniela , Soucek Ondrej , Matyskova Jana , Sumnik Zdenek , Lebl Jan

Background: Terminal Xp-deletion causes a variant of Turner syndrome (TS). Several studies described the associated phenotype: gonadal function is generally preserved and short stature is the major clinical feature.Case presentation: We present a family with vertical transmission of TS affecting six women in four subsequent generations. SNP-array indicates that the chromosomal aberration in this family includes terminal Xp-deletion and terminal Xq-duplic...

hrp0084fc5.6 | Endocrine Oncology/Turner | ESPE2015

Anti-Müllerian Hormone Levels in Patients with Turner Syndrome: Relation to Karyotype, Pubertal Development and GH Therapy

Hamza Rasha , Mira Marwa , Hamed Amira

Background: Gonadal dysgenesis in Turner syndrome (TS) results in pubertal delay or failure and infertility in most patients. However, up to 30% of girls with TS have spontaneous pubertal development and 2–5% have regular menstrual cycles before the onset of premature menopause. Serum anti-Mullerian (AMH) levels reflect the ovarian reserve in females, even in childhood.Objective and hypotheses: To Asses serum AMH levels in patients with TS and its r...